BioReliance® Introduces Advanced In Vitro ADME and Toxicology Services Designed to Improve Drug Safety and Efficacy BioReliance® (www.bioreliance.com), Sigma-Aldrich Corporation’s (NASDAQ: SIAL) biologics and early-development services business under SAFC® Commercial

Merck to Acquire Sigma-Aldrich to Enhance Position in Attractive Life Science Industry Merck to acquire Sigma-Aldrich for $140 per share in cash, valuing company at approx. $17 billion (€13.1 billion)

Illumina Reports Record Financial Results for Third Quarter of Fiscal Year 2014 Illumina, Inc. announced its financial results for the third quarter of 2014. Third quarter 2014 results: Revenue of

Lonza Half-Year Business Performance Fully on Track Business is fully on track with a CORE EBIT growth of 13.1% compared with the first half of 2013 despite currency headwinds Revenue

QIAGEN demonstrates expanded bioinformatics workflows at ASHG; strong market adoption as researchers analyse genomic data on more than a quarter-million samples in secure private cloud Translational research in cancer and